Results 71 to 80 of about 6,071 (199)

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children

, 2021
BACKGROUND: Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population.
Franco, Juan V.A., Ignacio Esteban, Escobar Liquitay, Camila Micaela, Pablo Roson Rodriguez, Juan VA Franco, Roson Rodriguez, Pablo, Esteban, Ignacio, Garegnani, Luis, Styrmisdóttir, Lea, Franco, Juan VA, Luis Garegnani, Lea Styrmisdóttir, Camila Micaela Escobar Liquitay   +12 more
core   +1 more source

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria (Versão em Português), 2017
Objective: This study aims to describe real world palivizumab use and effectiveness in high‐risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source

Respiratory syncytial virus infection and palivizumab: are families receiving accurate information

, 2012
The aim of this study was to assess the accuracy of information provided by medical practitioners to families regarding the efficacy and limitations of prophylaxis with palivizumab for respiratory syncytial virus (RSV) infection in infants.
Weiner, Joel H.
core   +1 more source

Valoración económica del palivizumab en prematuros en la Seguridad Social en Costa Rica

, 2020
RESUMEN Introducción: El virus sincitial respiratorio afecta la salud de prematuros y el palivizumab puede reducir sus complicaciones. En Costa Rica se desconoce la eficiencia del uso de esta tecnología sanitaria.
Collazo Herrera, Manuel, Jiménez Herrera, Luis Guillermo, Gálvez González, Ana María   +2 more
core  

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

BMC Infectious Diseases
Aim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection.
Jaime E. Ordóñez, Victor M. Huertas
doaj   +1 more source

Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region

Oman Medical Journal
Respiratory syncytial virus (RSV) infection poses a significant health threat to infants and young children. Considering the substantial burden in Gulf Cooperation Council (GCC) countries, prevention of RSV remains a major public health priority ...
Adel S. Alharbi, Abdul Rahman Alnemri, Ahmed Abushahin, Entesar Alhammadi, Huda Sulaiman Mohammed AlDhanhani, Laila Obaid , Mahmoud Saleh ElHalik, Mariam Kh Ayed   +7 more
doaj   +1 more source

Estudo de efectividade do Palivizumab [PDF]

, 2011
O Vírus Sincicial Respiratório (VSR) é o agente mais frequente das infecções respiratórias baixas nos primeiros dois anos de vida, sendo responsável por 50-90% dos episódios de bronquiolite nessa faixa etária.
Mira, Joana de Castela e
core  

Respiratory syncytial virus immunization patterns in Germany, 2015–2020

Human Vaccines & Immunotherapeutics
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated
Moritz Wick, Roman Kliemt, Anahita Poshtiban, Nils Kossack, Gerhard-Paul Diller, Samira Soudani, Mathieu Bangert, Rolf Kramer, Oliver Damm   +8 more
doaj   +1 more source

The HMPV F mutant bound motavizumab with higher affinity than palivizumab.

, 2016
Binding of the DS-7 Fab to wild-type (a) and motavizumab Fab RPM-1 (b) proteins using a BiOptix 404pi instrument. The wild-type HMPV F protein bound DS-7 with similar affinity as measured with the Biorad Proteon (Table 1).
Xiaolin Wen (2806171), Robert A. Lamb (278997), James E. Crowe Jr. (113691), George P. Leser (312089), Jarrod J. Mousa (2806174), Jennifer Pickens (2806168), Theodore S. Jardetzky (252519)   +6 more
core   +1 more source

Palivizumab compliance in congenital heart disease patients: factors related to compliance and altered lower respiratory tract infection viruses after palivizumab prophylaxis

, 2020
Background: Lower respiratory tract infections caused by respiratory syncytial virus can be severe during infancy, which requires admission to the hospital. These infections may be more severe especially in patients with congenital heart disease. Passive
Aykan, HAYRETTİN HAKAN, KARAGÖZ, TEVFİK, Aliyev, Emil, Sel, Kutay, ALEHAN, DURSUN, Donmez, Yasemin Nuran, AYPAR, EBRU   +6 more
core   +1 more source